Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Regulatory News (SNG)

  • There is currently no data for SNG

Holding(s) in Company

21 Oct 2020 09:45

RNS Number : 7807C
Synairgen plc
21 October 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Synairgen plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

X

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Bong Koh and Nimish Shah (as the voting members of VHCP Management II, LLC and VHCP Management III, LLC)

 

City and country of registered office (if applicable)

New York, NY, U.S.A.

4. Full name of shareholder(s) (if different from 3.)v

Name

See section 11 below

City and country of registered office (if applicable)

New York, NY, U.S.A.

5. Date on which the threshold was crossed or reachedvi:

19 October 2020

6. Date on which issuer notified (DD/MM/YYYY):

21 October 2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

4.64%

4.64%

164,910,914

Position of previous notification (if

applicable)

5.91%

5.91%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary Shares

ISIN: GB00B0381Z20

7,655,000

4.64%

SUBTOTAL 8. A

7,655,000

4.64%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Bong Koh and Nimish Shah (as the voting members of VHCP Management II, LLC and VHCP Management III, LLC)

4.64%

N/A

4.64%

Bong Koh and Nimish Shah (as the votingmembers of VHCP Management II, LLC)

 

N/A

N/A

N/A

VHCP Management II, LLC

 

N/A

N/A

N/A

Bong Koh and Nimish Shah (as the votingmembers of VHCP Management III, LLC)

 

N/A

N/A

N/A

VHCP Management III, LLC

 

N/A

N/A

N/A

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

Bong Koh and Nimish Shah are the voting members of VHCP Management II, LLC and VHCP Management III, LLC.

 

VCHP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. and manager of VHCP Co-Investment Holdings II, LLC, each of which holds shares in Synairgen plc falling below the notifiable threshold.

 

VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and manager of VHCP Co-Investment Holdings III, LLC, each of which holds shares in Synairgen plc falling below the notifiable threshold.

 

All percentages are based on the notified current issued share capital of Synairgen plc of 164,910,914 ordinary shares.

 

 

 

Place of completion

New York, NY, U.S.A.

Date of completion

21 October 2020

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFIFVTIRLLFII
Date   Source Headline
11th May 20205:41 pmRNSHolding(s) in Company
6th May 20205:07 pmRNSHolding(s) in Company
5th May 202011:05 amRNSSecond Price Monitoring Extn
5th May 202011:00 amRNSPrice Monitoring Extension
30th Apr 202012:09 pmRNSExtension of clinical study in COVID-19 patients
28th Apr 20205:16 pmRNSHolding(s) in Company
24th Apr 20205:10 pmRNSHolding(s) in Company
16th Apr 20205:35 pmRNSHolding(s) in Company
15th Apr 20201:30 pmRNSHolding(s) in Company
14th Apr 20202:06 pmRNSSecond Price Monitoring Extn
14th Apr 20202:00 pmRNSPrice Monitoring Extension
14th Apr 202012:00 pmRNSResult of General Meeting
14th Apr 202011:06 amRNSSecond Price Monitoring Extn
14th Apr 202011:00 amRNSPrice Monitoring Extension
14th Apr 20209:00 amRNSPrice Monitoring Extension
8th Apr 20204:41 pmRNSSecond Price Monitoring Extn
8th Apr 20204:36 pmRNSPrice Monitoring Extension
1st Apr 20204:56 pmRNSHolding(s) in Company
31st Mar 20207:00 amRNSCommencement of dosing in COVID-19 trial
30th Mar 20204:42 pmRNSSecond Price Monitoring Extn
30th Mar 20204:36 pmRNSPrice Monitoring Extension
30th Mar 202011:05 amRNSSecond Price Monitoring Extn
30th Mar 202011:00 amRNSPrice Monitoring Extension
30th Mar 20209:05 amRNSSecond Price Monitoring Extn
30th Mar 20209:00 amRNSPrice Monitoring Extension
27th Mar 20203:21 pmRNSHolding(s) in Company
26th Mar 20209:00 amRNSResult of Fundraising
25th Mar 20201:45 pmRNSProposed Fundraising
25th Mar 202011:05 amRNSSecond Price Monitoring Extn
25th Mar 202011:00 amRNSPrice Monitoring Extension
25th Mar 20208:24 amRNSHolding(s) in Company
23rd Mar 202011:05 amRNSSecond Price Monitoring Extn
23rd Mar 202011:00 amRNSPrice Monitoring Extension
23rd Mar 20209:05 amRNSSecond Price Monitoring Extn
23rd Mar 20209:00 amRNSPrice Monitoring Extension
20th Mar 20204:48 pmRNSSecond Price Monitoring Extn
20th Mar 20204:40 pmRNSPrice Monitoring Extension
20th Mar 20202:00 pmRNSPrice Monitoring Extension
19th Mar 20202:06 pmRNSSecond Price Monitoring Extn
19th Mar 20202:01 pmRNSPrice Monitoring Extension
19th Mar 20209:05 amRNSSecond Price Monitoring Extn
19th Mar 20209:00 amRNSPrice Monitoring Extension
18th Mar 20207:00 amRNSSynairgen to start trial of SNG001 in COVID-19
10th Mar 20204:36 pmRNSPrice Monitoring Extension
17th Oct 20193:53 pmRNSHoldings in Company
16th Oct 20197:30 amRNSHolding(s) in Company
30th Sep 20197:00 amRNSHalf-year Report
27th Sep 20197:00 amRNSPhase II Biomarker Data for SNG001 to be presented
24th Jul 20197:00 amRNSPhase II Clinical Trial Update
8th Jul 20195:48 pmRNSHoldings in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.